More aggressive molecular subtypes such as triple negative and HER2-enriched cancers have a propensity for metastatic disease and thus require treatment with either cytotoxic chemotherapy or the combination of cytotoxic chemotherapy and targeted anti-HER2 treatment [4–6]. The gene discussed is ERBB2; the disease is metastatic neoplasm.